stockrowCodexis, Inc.
CDXSCodexis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.4 million, up 18.6% from fiscal 2024.
- Revenue
- −2.69%
- EPS
- +18.8%
- Free cash flow
- +48.6%
- Total debt
- −14.1%
Quarter to June 2026, against a year earlier
Follow CDXS
Alert me
Codexis, Inc. (CDXS) Return on invested capital
Codexis, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −151.2%, up 67.2 percentage points from fiscal 2025 (−218.4%). Over the past ten years it has ranged from −719.4% (fiscal 2016) to 0.00% (fiscal 2017); the current reading is higher than 27% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −218.4% | (51.13) |
| FY2024 | −167.2% | 35.55 |
| FY2023 | −202.8% | (170.99) |
| FY2022 | −31.8% | (16.13) |
| FY2021 | −15.7% | 20.22 |
| FY2020 | −35.9% | (15.93) |
| FY2019 | −20.0% | 189.96 |
| FY2018 | −209.9% | (209.91) |
| FY2017 | 0.00% | 719.42 |
| FY2016 | −719.4% | (189.26) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ENGN enGene Therapeutics Inc compare | 0.00% |
| ANIX ANIXA BIOSCIENCES INC compare | 0.00% |
| AVXL Anavex Life Sciences Corp. compare | 0.00% |
| IMUX Immunic, Inc. compare | 0.00% |
| FHTX Foghorn Therapeutics Inc. compare | 0.00% |
| OTLK Outlook Therapeutics, Inc. compare | 0.00% |
| PDSB PDS Biotechnology Corporation compare | 0.00% |
| CDXS Codexis, Inc. | −151.2% |
| VYGR Voyager Therapeutics, Inc. compare | −249.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)